Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 3 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 9:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 3088 Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs). Bader J McKean M, Fontana E, Falchook G Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2593 Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/ PD-L1. Carneiro A Aljumaily R, Falchook G Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2527 Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors. Rasco D McKean M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2054 Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort. Strowd R Bauer T Central Nervous System Tumors 9:00am - 12:00pm Hall A Poster 2068 Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results. Wen P Johnson M, Henry J, Battiste J, Alnahhas I Central Nervous System Tumors 9:00am - 12:00pm Hall A Poster 2599 IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors. Aggen D McKean M, Guancial E, Bashir B Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2595 Phase 1/2 study of XTX202, a tumor- activated IL-2βγ, in advanced solid tumors. Chahoud J McKean M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2596 Phase I dose-escalation and cohort expansion study of the anti- BTLA antibody, tifcemalimab, in combination with toripalimab (anti- PD-1) in heavily pretreated patients (pts) with advanced malignancies. Ma V Schilder R, McKean M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2621 A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to- treat gastrointestinal tumors. Kim R Johnson M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2563 Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors. Naing A Johnson M Developmental Therapeutics— Immunotherapy